CN117919388A - Recombinant urate oxidase freeze-dried powder and preparation method thereof - Google Patents
Recombinant urate oxidase freeze-dried powder and preparation method thereof Download PDFInfo
- Publication number
- CN117919388A CN117919388A CN202410119202.1A CN202410119202A CN117919388A CN 117919388 A CN117919388 A CN 117919388A CN 202410119202 A CN202410119202 A CN 202410119202A CN 117919388 A CN117919388 A CN 117919388A
- Authority
- CN
- China
- Prior art keywords
- urate oxidase
- parts
- recombinant urate
- recombinant
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010092464 Urate Oxidase Proteins 0.000 title claims abstract description 41
- 229940005267 urate oxidase Drugs 0.000 title claims abstract description 38
- 239000000843 powder Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title abstract description 8
- -1 maltose compound Chemical class 0.000 claims abstract description 12
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 11
- 240000009120 Phyllanthus emblica Species 0.000 claims abstract description 11
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 10
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 10
- 229930195725 Mannitol Natural products 0.000 claims abstract description 10
- 235000004279 alanine Nutrition 0.000 claims abstract description 10
- 235000010355 mannitol Nutrition 0.000 claims abstract description 10
- 239000000594 mannitol Substances 0.000 claims abstract description 10
- 235000013923 monosodium glutamate Nutrition 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- 229940073490 sodium glutamate Drugs 0.000 claims abstract description 10
- 235000020696 epimedium extract Nutrition 0.000 claims abstract description 8
- 239000006172 buffering agent Substances 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 239000003223 protective agent Substances 0.000 claims description 9
- 239000002131 composite material Substances 0.000 claims description 8
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 108090000854 Oxidoreductases Proteins 0.000 claims description 5
- 102000004316 Oxidoreductases Human genes 0.000 claims description 5
- 241000228197 Aspergillus flavus Species 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 229940088598 enzyme Drugs 0.000 abstract description 3
- 238000000465 moulding Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- NUCLJNSWZCHRKL-UHFFFAOYSA-N allantoic acid Chemical compound NC(=O)NC(C(O)=O)NC(N)=O NUCLJNSWZCHRKL-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
The application discloses recombinant urate oxidase freeze-dried powder and a preparation method thereof, belonging to the technical field of biological enzyme freeze-dried powder. The freeze-dried powder comprises: recombinant urate oxidase, phyllanthus emblica extract, epimedium extract, buffering agent, mannitol, maltose compound protectant and alanine and sodium glutamate compound excipient. The application improves the stability of recombinant urate oxidase freeze-dried powder and has good molding.
Description
Technical Field
The invention relates to the technical field of biological enzyme freeze-dried powder, in particular to recombinant urate oxidase freeze-dried powder and a preparation method thereof.
Background
Urate oxidase is a key enzyme for purine metabolism in organisms, and catalyzes uric acid to oxidize to form allantoic acid, and consists of four identical subunits, each subunit contains 301 amino acids and has a molecular weight of about 34 kD. It converts uric acid into allantoin, which is safe for the human body and is a highly soluble compound that is easily excreted by the kidneys. But the urate oxidase content in human body is very low. Currently, a large number of urate oxidases are used which are produced by genetic engineering methods, i.e. recombinant urate oxidases. Uricase drugs mainly comprise recombinant aspergillus flavus oxidase and polyethylene glycol recombinant oxidase, and both drugs have the effects of rapidly and strongly reducing blood uric acid, but although the two drugs are clinically effective, the conjugates are required to have preparations which can be stored for a long time during production and distribution to health care institutions in clinical practice.
The freeze-drying method is a method of sublimating water from a composition after the composition is frozen. The advantage of the freeze-drying process in this process is that the original form and active ingredient of the material can be maintained. Recombinant urate oxidase is thus combined with freeze-drying to be a new research direction.
In recent years, traditional Chinese medicine treatment becomes a hotspot of pharmaceutical research, and a combined mode of Chinese and western medicine may provide a new idea for treating diseases such as gout.
Disclosure of Invention
The invention aims to improve the stability of recombinant urate oxidase freeze-dried powder and form the recombinant urate oxidase freeze-dried powder well by providing the freeze-dried powder.
In order to achieve the aim, the invention discloses recombinant urate oxidase freeze-dried powder and a preparation method thereof, and the specific technical scheme is as follows:
firstly, the invention discloses recombinant urate oxidase freeze-dried powder, which comprises the following components in parts by mass:
1-4 parts of recombinant urate oxidase;
5-10 parts of phyllanthus emblica extract;
1-8 parts of epimedium extract;
15-35 parts of mannitol and maltose compound protective agent;
10-18 parts of alanine and sodium glutamate composite excipient;
20-30 parts of buffering agent.
Preferably, the recombinant urate oxidase is recombinant aspergillus flavus oxidase or pegylated urate oxidase.
In addition, the invention also provides a preparation method of the recombinant urate oxidase freeze-dried powder, which comprises the following steps: dissolving recombinant urate oxidase, phyllanthus emblica extract, epimedium extract, mannitol, maltose compound protective agent, alanine and sodium glutamate compound excipient in the above weight proportion in a solvent, regulating the pH to 7.5, subpackaging into a freezing tube, respectively performing prefreezing period, primary drying, analytical drying to obtain the final product, and preserving below-80 ℃.
Preferably, the solvent is distilled water.
Preferably, the prefreezing period conditions are: maintaining at-60deg.C for more than 2 hr.
Preferably, the primary drying conditions are: the vacuum degree is 12-17e-2mbar, the temperature is gradually increased from-60 ℃ to 20 ℃ for 15-20 hours.
Preferably, the analytical drying conditions are: vacuum degree is 0.1-2e-2mbar, and temperature is 20deg.C for 5-10h.
The beneficial effects of the invention are that
Compared with the prior art, the invention improves the stability of the recombinant urate oxidase freeze-dried powder and has good molding by adding the composite protective agent and the composite excipient into the freeze-dried powder; in addition, the traditional Chinese medicine extract is added, so that the treatment effect of the freeze-dried powder is improved.
Detailed Description
Firstly, the invention provides recombinant urate oxidase freeze-dried powder, which comprises the following components in parts by mass:
1-4 parts of recombinant urate oxidase;
5-10 parts of phyllanthus emblica extract;
1-8 parts of epimedium extract;
15-35 parts of mannitol and maltose compound protective agent;
10-18 parts of alanine and sodium glutamate composite excipient;
20-30 parts of buffering agent.
Preferably, the recombinant urate oxidase is recombinant aspergillus flavus oxidase or pegylated urate oxidase.
In addition, the invention also provides a preparation method of the recombinant urate oxidase freeze-dried powder, which comprises the following steps: dissolving recombinant urate oxidase, phyllanthus emblica extract, epimedium extract, mannitol, maltose compound protective agent, alanine and sodium glutamate compound excipient in distilled water according to the mass portion ratio, regulating the PH to 7.5, subpackaging into a freezing tube, respectively performing prefreezing period, primary drying, analytical drying to obtain a finished product, and preserving below-80 ℃. Preferably, the prefreezing period conditions are: maintaining at-60deg.C for more than 2 hr. Preferably, the primary drying conditions are: the vacuum degree is 12-17e-2mbar, the temperature is gradually increased from-60 ℃ to 20 ℃ for 15-20 hours. Preferably, the analytical drying conditions are: vacuum degree is 0.1-2e-2mbar, and temperature is 20deg.C for 5-10h.
The method for extracting the phyllanthus emblica extract comprises the steps of adding phyllanthus emblica into a multifunctional extraction tank, adding purified water for multiple extraction, filtering, combining the extracting solutions, centrifuging, taking supernatant, concentrating under reduced pressure, drying, and crushing to obtain the phyllanthus emblica active extract.
The herba Epimedii extract is prepared by extracting herba Epimedii with purified water for several times in a multifunctional extraction tank, filtering, mixing extractive solutions, centrifuging, concentrating supernatant under reduced pressure, drying, and pulverizing to obtain herba Epimedii active extract.
Example 1
The recombinant urate oxidase freeze-dried powder comprises the following components in parts by weight:
4 parts of recombinant urate oxidase;
8 parts of phyllanthus emblica extract;
6 parts of epimedium extract;
20 parts of mannitol and maltose compound protective agent;
16 parts of alanine and sodium glutamate composite excipient;
30 parts of buffer.
Wherein in the mannitol and maltose composite protective agent, the mass ratio of mannitol to maltose is 2:5; in the alanine and sodium glutamate composite excipient, the mass ratio of the alanine to the sodium glutamate is 1:2.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.
Claims (7)
1. The recombinant urate oxidase freeze-dried powder is characterized by comprising the following components in parts by mass:
1-4 parts of recombinant urate oxidase;
5-10 parts of phyllanthus emblica extract;
1-8 parts of epimedium extract;
15-35 parts of mannitol and maltose compound protective agent;
10-18 parts of alanine and sodium glutamate composite excipient;
20-30 parts of buffering agent.
2. The recombinant urate oxidase lyophilized powder according to claim 1, wherein the recombinant urate oxidase is recombinant aspergillus flavus oxidase or pegylated urate oxidase.
3. A method for preparing recombinant urate oxidase freeze-dried powder, which is characterized by comprising the following steps: dissolving recombinant urate oxidase, phyllanthus emblica extract, epimedium extract, mannitol, maltose compound protective agent, alanine and sodium glutamate compound excipient in the above weight proportion in a solvent, regulating the pH to 7.5, subpackaging into a freezing tube, respectively performing prefreezing period, primary drying, analytical drying to obtain the final product, and preserving below-80 ℃.
4. The method for preparing recombinant urate oxidase lyophilized powder according to claim 5, wherein the solvent is distilled water.
5. The method for preparing recombinant urate oxidase lyophilized powder according to claim 5, wherein the prefreezing period condition is: maintaining at-60deg.C for more than 2 hr.
6. The method for preparing recombinant urate oxidase lyophilized powder according to claim 5, wherein the primary drying conditions are as follows: the vacuum degree is 12-17e-2mbar, the temperature is gradually increased from-60 ℃ to 20 ℃ for 15-20 hours.
7. The method for preparing recombinant urate oxidase lyophilized powder according to claim 5, wherein the analytical drying conditions are as follows: vacuum degree is 0.1-2e-2mbar, and temperature is 20deg.C for 5-10h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410119202.1A CN117919388A (en) | 2024-01-29 | 2024-01-29 | Recombinant urate oxidase freeze-dried powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410119202.1A CN117919388A (en) | 2024-01-29 | 2024-01-29 | Recombinant urate oxidase freeze-dried powder and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117919388A true CN117919388A (en) | 2024-04-26 |
Family
ID=90766513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410119202.1A Pending CN117919388A (en) | 2024-01-29 | 2024-01-29 | Recombinant urate oxidase freeze-dried powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117919388A (en) |
-
2024
- 2024-01-29 CN CN202410119202.1A patent/CN117919388A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5888506A (en) | Methioninase formulations | |
| KR102456734B1 (en) | A genus of Staphylococcus strain and uses thereof | |
| CN112999127B (en) | Gentiana scabra bunge compound enzyme and preparation method and application thereof | |
| KR101810385B1 (en) | Composition comprising GDF11 and uses thereof | |
| CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| KR102032116B1 (en) | Method for preparing tea fermented materials and cosmetic composition comprising the same | |
| TWI744971B (en) | Use of extraction of auricularia polytricha for preparing composition for inducing differentiation of non-polarized immune cells into anti-inflammatory immune cells | |
| CN117919388A (en) | Recombinant urate oxidase freeze-dried powder and preparation method thereof | |
| KR102560091B1 (en) | Novel Scalp-derived Lacticaseibacillus rhamnosus sc.Q5 strain having antibacterial effect against hair loss-inducing harmful bacteria and hair loss prevention activity and use thereof | |
| CN101327172A (en) | Alkaline fibroblast growth factor and use of its composition in preparing beauty treatment cosmetics | |
| CN114957394B (en) | Polypeptide PM-7 for promoting skin repair and application thereof | |
| CN117683081B (en) | Antihypertensive peptide and application thereof in antihypertensive products | |
| CN114344187B (en) | Davalia macrophylla polypeptide composition and preparation method and application thereof | |
| TWI354562B (en) | Enzymatic hydrolysate of algae for promoting growt | |
| US6759065B1 (en) | Extraction method, pharmaceutical composition and a cosmetic composition | |
| KR102053261B1 (en) | Composition for improving hair and scalp comprising fermented medical plant extracts and method for preparing the same | |
| CN112442104A (en) | Fermentation method for preparing lycium barbarum bioactive peptide, method and application thereof, inhibitor and functional food | |
| KR102528139B1 (en) | Cosmetic composition containing Camellia Sinensis Leaf exosome and Avena Sativa(Oat) Kernel exosome | |
| KR102316637B1 (en) | Bacillus subtilis strain derived from Centella asiatica and its use for improving skin conditions | |
| KR102687359B1 (en) | Novel Scalp-derived Lacticaseibacillus rhamnosus sc.Q5 strain having hair growth promotion effect and use thereof | |
| KR102102137B1 (en) | A composition for preventing or treating tinea pedis comprising an fermentative product of an Rhus veniciflua | |
| CN107661366B (en) | Preparation method of gynostemma pentaphylla bioactive substance and human-derived stem cell active factor composition for preventing cell canceration | |
| CN101525371A (en) | Method for extracting insulin-like growth factor (IGF-1) from pilose antler | |
| CN116549346A (en) | Composition for improving euepidermis connecting layer and application thereof | |
| CN113995845A (en) | Ivermectin preparation and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |